JPS5980609A - コレステロ−ル低下活性画分の製造方法及び当該活性画分含有抗動脈硬化剤 - Google Patents
コレステロ−ル低下活性画分の製造方法及び当該活性画分含有抗動脈硬化剤Info
- Publication number
- JPS5980609A JPS5980609A JP57189253A JP18925382A JPS5980609A JP S5980609 A JPS5980609 A JP S5980609A JP 57189253 A JP57189253 A JP 57189253A JP 18925382 A JP18925382 A JP 18925382A JP S5980609 A JPS5980609 A JP S5980609A
- Authority
- JP
- Japan
- Prior art keywords
- streptococcus
- active fraction
- fraction
- cholesterol level
- active
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 title abstract description 17
- 238000002360 preparation method Methods 0.000 title description 3
- 230000001580 bacterial effect Effects 0.000 claims abstract description 22
- 241000194017 Streptococcus Species 0.000 claims abstract description 18
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 7
- 239000000284 extract Substances 0.000 claims abstract description 6
- 241000194031 Enterococcus faecium Species 0.000 claims abstract description 4
- 241000194049 Streptococcus equinus Species 0.000 claims abstract description 3
- 244000005700 microbiome Species 0.000 claims description 10
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- 241000194024 Streptococcus salivarius Species 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract description 4
- 210000004369 blood Anatomy 0.000 abstract description 4
- 239000008280 blood Substances 0.000 abstract description 4
- 231100000252 nontoxic Toxicity 0.000 abstract description 4
- 230000003000 nontoxic effect Effects 0.000 abstract description 4
- 239000007788 liquid Substances 0.000 abstract description 3
- 206010003210 Arteriosclerosis Diseases 0.000 abstract description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 abstract description 2
- 208000020346 hyperlipoproteinemia Diseases 0.000 abstract description 2
- 239000012528 membrane Substances 0.000 abstract description 2
- 241000194032 Enterococcus faecalis Species 0.000 abstract 1
- 238000012258 culturing Methods 0.000 abstract 1
- 201000005577 familial hyperlipidemia Diseases 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 239000002994 raw material Substances 0.000 abstract 1
- 241000894006 Bacteria Species 0.000 description 10
- 238000011160 research Methods 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 241000700159 Rattus Species 0.000 description 6
- 239000002504 physiological saline solution Substances 0.000 description 6
- 239000003814 drug Substances 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 238000003809 water extraction Methods 0.000 description 4
- 229930091371 Fructose Natural products 0.000 description 3
- 239000005715 Fructose Substances 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 102100025027 E3 ubiquitin-protein ligase TRIM69 Human genes 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 101000830203 Homo sapiens E3 ubiquitin-protein ligase TRIM69 Proteins 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 201000001883 cholelithiasis Diseases 0.000 description 1
- KNHUKKLJHYUCFP-UHFFFAOYSA-N clofibrate Chemical compound CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 KNHUKKLJHYUCFP-UHFFFAOYSA-N 0.000 description 1
- 229960001214 clofibrate Drugs 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 125000000151 cysteine group Chemical class N[C@@H](CS)C(=O)* 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 101150092645 fliF gene Proteins 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- BJHIKXHVCXFQLS-UYFOZJQFSA-N fructose group Chemical group OCC(=O)[C@@H](O)[C@H](O)[C@H](O)CO BJHIKXHVCXFQLS-UYFOZJQFSA-N 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000003229 sclerosing agent Substances 0.000 description 1
- 230000001932 seasonal effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- YWYZEGXAUVWDED-UHFFFAOYSA-N triammonium citrate Chemical compound [NH4+].[NH4+].[NH4+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O YWYZEGXAUVWDED-UHFFFAOYSA-N 0.000 description 1
- 235000011046 triammonium citrate Nutrition 0.000 description 1
- 239000001393 triammonium citrate Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 230000002747 voluntary effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 229940100445 wheat starch Drugs 0.000 description 1
Landscapes
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Compounds Of Unknown Constitution (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP57189253A JPS5980609A (ja) | 1982-10-29 | 1982-10-29 | コレステロ−ル低下活性画分の製造方法及び当該活性画分含有抗動脈硬化剤 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP57189253A JPS5980609A (ja) | 1982-10-29 | 1982-10-29 | コレステロ−ル低下活性画分の製造方法及び当該活性画分含有抗動脈硬化剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS5980609A true JPS5980609A (ja) | 1984-05-10 |
| JPH0534342B2 JPH0534342B2 (enrdf_load_stackoverflow) | 1993-05-21 |
Family
ID=16238191
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP57189253A Granted JPS5980609A (ja) | 1982-10-29 | 1982-10-29 | コレステロ−ル低下活性画分の製造方法及び当該活性画分含有抗動脈硬化剤 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS5980609A (enrdf_load_stackoverflow) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5980610A (ja) * | 1982-10-29 | 1984-05-10 | Advance Res & Dev Co Ltd | コレステロ−ル低下活性画分の製造方法及び当該活性画分含有抗動脈硬化剤 |
| JPS59109181A (ja) * | 1982-12-16 | 1984-06-23 | Advance Res & Dev Co Ltd | コレステロ−ル低下活性画分の製造方法及び当該活性画分含有抗動脈硬化剤 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5980610A (ja) * | 1982-10-29 | 1984-05-10 | Advance Res & Dev Co Ltd | コレステロ−ル低下活性画分の製造方法及び当該活性画分含有抗動脈硬化剤 |
-
1982
- 1982-10-29 JP JP57189253A patent/JPS5980609A/ja active Granted
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5980610A (ja) * | 1982-10-29 | 1984-05-10 | Advance Res & Dev Co Ltd | コレステロ−ル低下活性画分の製造方法及び当該活性画分含有抗動脈硬化剤 |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5980610A (ja) * | 1982-10-29 | 1984-05-10 | Advance Res & Dev Co Ltd | コレステロ−ル低下活性画分の製造方法及び当該活性画分含有抗動脈硬化剤 |
| JPS59109181A (ja) * | 1982-12-16 | 1984-06-23 | Advance Res & Dev Co Ltd | コレステロ−ル低下活性画分の製造方法及び当該活性画分含有抗動脈硬化剤 |
Also Published As
| Publication number | Publication date |
|---|---|
| JPH0534342B2 (enrdf_load_stackoverflow) | 1993-05-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA1246445A (en) | Intestinal microflora-improving agent | |
| EP0181170B1 (en) | Hypocholesterolemically active products | |
| US4797278A (en) | Hypocholesterolemically and/or hypotriglyceridemically active products and their use | |
| US6942857B2 (en) | Microorganisms for preventing and/or treating obesity or diabetes mellitus | |
| EP0228861B1 (en) | Agent for reducing the dimethylnitrosoamine level | |
| JPS58131917A (ja) | 抗動脈硬化剤 | |
| JPS5980609A (ja) | コレステロ−ル低下活性画分の製造方法及び当該活性画分含有抗動脈硬化剤 | |
| JPH0365362B2 (enrdf_load_stackoverflow) | ||
| JP2969017B2 (ja) | 感染防御剤 | |
| CA1286623C (en) | Liver function-improving agent and blood pressure- lowering agent | |
| WO2005077390A1 (ja) | 血糖値低下剤、糖尿病治療・予防剤及びその製造方法 | |
| JPS5980610A (ja) | コレステロ−ル低下活性画分の製造方法及び当該活性画分含有抗動脈硬化剤 | |
| JP5451703B2 (ja) | Ｉｉ型肺胞上皮細胞活性剤 | |
| JP3272023B2 (ja) | 白血球減少治療剤 | |
| US4833129A (en) | Hypocholesterolemically and/or hypotriglyceridemically active RNA fractions | |
| JPS63280027A (ja) | 抗高脂血症剤 | |
| CA1276897C (en) | Hypocholesterolemically active rna fractions | |
| JPS59109181A (ja) | コレステロ−ル低下活性画分の製造方法及び当該活性画分含有抗動脈硬化剤 | |
| KR100280366B1 (ko) | 리팜피신과 각종 항생제에 내성을 갖는 신규 변이주인 엔테로코 | |
| JP2841237B2 (ja) | 血圧降下作用を有する菌体水抽出物を有効成分とする血圧降下剤 | |
| JPS59109180A (ja) | コレステロ−ル低下活性画分の製造方法及び当該活性画分含有抗動脈硬化剤 | |
| JPH07138169A (ja) | 抗膀胱炎用剤 | |
| JP2024102776A (ja) | 下痢・軟便の予防・軽減素材 | |
| JPS59109182A (ja) | コレステロ−ル低下活性画分の製造方法及び当該活性画分含有抗動脈硬化剤 |